Results 101 to 110 of about 24,979 (220)
Characterization of synuclein-GM1 interaction.
, 2014 A. Cumulative reaction enthalpy of αS vs. NAA-αS (each at 5 µM) upon vesicle titration with GM1 vesicles is shown as a function of lipid/protein ratio. Experiments were conducted at 25°C. Note the strongly increased heat release for NAA-αS upon titration
Eric S. Luth (606172) +3 more
core +1 more source
Revista Methodo, 2018 Una de las estrategias terapéuticas actuales contra el cáncer está orientada a mejorar la efectividad de los fármacos anticancerígenos existentes mediante el desarrollo de sistemas innovadores de transporte [13,14] que permitan modificar las ...
Garro GA
doaj
Comparison of efficacy of sialidase infusion versus systemic GM1 administration.
, 2015 At all doses, Vibrio cholerae sialidase (VCS) infusion was less effective than systemically administered GM1 at increasing striatal dopamine levels (A ...
Thomas N. Seyfried (217811) +3 more
core +1 more source
Interaction analysis of GM1-Glc-immobilized fluorescent nanoparticles (GM1-Glc-SFNPs) with lectins.
, 2015 (A) Analysis of interactions between GM1-Glc-SFNPs and lectins. Visual image of the mixture of GM1-Glc-SFNPs and proteins under UV irradiation. (B) Fluorescence spectra of the supernatant monitored by an excitation wavelength at 360 nm.
Nobuhiro Yuki (60770) +5 more
core +1 more source
A METHOD FOR TREATMENT OF GM1 GANGLIOSIDOSIS
, 2015 The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 ...
곽재은 +4 more
core
Pharmacokinetics of GM1 Ganglioside Following Parenteral Administration
, 1990 The pharmacokinetic parameters of monosialotetrahexosylganglioside (GM1) have been determined in healthy volunteers at 3 dose levels: 100, 200, 300 mg. Each dose was administered to separate groups of 12 volunteers.
Aldo Panucci +5 more
core +1 more source
Complex of GM1 and GD1a (cM1/GD1a).
, 2015 (A) Immunostaining with IgG antibodies from Patient 4. Bovine brain ganglioside mixture (lane 1), authentic GM1b (lane 2) and a mixture of GM1 and GD1a (lane 3) were spotted on a thin-layer chromatogram plate and developed with a solvent.
Nobuhiro Yuki (60770) +3 more
core +1 more source
Ganglioside GM1 (GM1) for Huntington's disease (HD) [PDF]
Science-Business eXchange, 2012 openaire +1 more source
Therapeutic developments for neurodegenerative GM1 gangliosidosis [PDF]
GM1 gangliosidosis (GM1) is a rare but fatal neurodegenerative disease caused by dysfunction or lack of production of lysosomal enzyme, β-galactosidase, leading to accumulation of substrates.
Jessica Larsen +3 more
core +1 more source
Clinical relevance of anti-GM1 IgM antibodies
, 1991 Anti-GM1 IgM antibodies were found in 23% of 56 patients with motor neuron disease (MND), in 19% of 69 patients with neuropathy and in 7% of 107 controls with other neurological and non-neurological diseases. Most patients had anti-GM1 IgM titers of 1:80
E. Nobile-Orazio, M. Carpo, G. Scarlato
core +2 more sources